UNLOXCYT

(Cosibelimab)

ApprovedMonoclonal antibody

Sun Pharmaceutical Industries, Inc.

UNLOXCYT is one of 109 small molecule programs targeting Lymphoma. It is currently in Approved.

Indications

Total Trials

Active Trials

108

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

LymphomaActive, not recruiting

Kidney TransplantActive, not recruiting

Pancreatic Ductal AdenocarcinomaActive, not recruiting

LymphomaPhase 1

Active, not recruiting

Kidney TransplantApproved

Active, not recruiting

Pancreatic Ductal AdenocarcinomaPhase 1

Active, not recruiting

Competition

Competitive Landscape

1774 competitors in Lymphoma

#DrugCompanyPhaseTrials

UNLOXCYT

Sun Pharmaceutical Industries, Inc.

Approved

1 2

Oncaspar

SServier

Preclinical

15 3

Zofran

Novartis

Preclinical

2 4

Norvir

AbbVie

Preclinical

1 5

Wellcovorin

GGlaxo Dba Glaxosmithkline

Preclinical

4 6

Tafasitamab

Incyte

Preclinical

7 7

Emend

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 8

Kenalog

BBausch Health Americas, Inc.

Preclinical

1 9

Decadron

QQuince Therapeutics S.p.A.

Preclinical

—10

Solu-Medrol

MMassachusetts Eye and Ear Infirmary

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 1Not yet recruiting

Pancreatic Ductal Adenocarcinoma

NCT06981806

Q4 2032

Post-ApprovalNot yet recruiting

Kidney Transplant

NCT07426484

Clinical

Trials by Indication[1]

Kidney Transplant1 trial

Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy

Not yet recruiting·—·Phase 4·NCT07426484·80 enrolled

Non-squamous NSCLC1 trial

Study of Pemetrexed+Platinum Chemotherapy With or Without Cosibelimab in First Line Metastatic Non-squamous NSCLC

Terminated·CCheckpoint Therapeutics, Inc.·Phase 3·NCT04786964·25 enrolled

Pancreatic Ductal Adenocarcinoma1 trial

Phase I Study of Cosibelimab and Balixafortide in Metastatic Pancreatic Ductal Adenocarcinoma

Not yet recruiting·AArsen Osipov·Phase 1·NCT06981806·24 enrolled

Lymphoma1 trial

Study of Cosibelimab in Subjects With Relapsed or Refractory Lymphoma

Terminated·TTG Therapeutics, Inc.·Phase 1·NCT03778073·18 enrolled

Regulatory

FDA Approval Timeline[4]

Dec 13, 2024

UNLOXCYT

BLA BLA761297

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Cosibelimab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Cosibelimab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Cosibelimab. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (BLA BLA761297). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Sun Pharmaceutical Industries, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Approved[1]
Company: Sun Pharmaceutical Industries, Inc.

UNLOXCYT

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q4 2032

Trials by Indication[1]

Kidney Transplant1 trial

Non-squamous NSCLC1 trial

Pancreatic Ductal Adenocarcinoma1 trial

Lymphoma1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News